News & Info


Page 1 of 3012345...102030...Last »

January 11, 2018

Free Information Available to the Public for Glaucoma Awareness Month

Posted in: Latest News

Cases of Glaucoma, the “Sneak Thief of Sight,” Projected to Increase Significantly in Near Future As the population of the United States ages, the number of age-related eye disease cases is projected to grow.  Glaucoma, one of the most common eye diseases, currently affects nearly 3 million people ages 40 and older, according to the
read more »

January 8, 2018

New Educational Toolkit Launched to Improve Understanding of Age-related Macular Degeneration

Posted in: Latest News

A global coalition of patients and representative groups concerned with vision health, aging, and avoidable blindness has launched a central hub designed to bring the most up-to-date information on the various forms of Age-related Macular Degeneration (AMD) to patients, their representatives, health care providers, and policy makers. . The Toolkit, available at www.RETINA-AMD.org, was developed
read more »

December 21, 2017

Apellis Entering Phase 3 Trials for Dry Macular Degeneration

Posted in: Latest News, Research and Developments

Apellis Pharmaceuticals has announced that it has finalized the trial design for its planned Phase 3 program evaluating APL-2 for the treatment of patients with geographic atrophy (GA), aka dry macular degeneration. The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical studies to assess the efficacy
read more »

December 20, 2017

FDA Approves First Gene Therapy for Inherited Retinal Dystrophy

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

The U.S. Food and Drug Administration (FDA) has approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy developed by Spark Therapeutics, to treat an inherited form of vision loss that can result in blindness.  The most prevalent inherited retinal dystrophies are retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Stargardt disease (SD), all of which have
read more »

December 14, 2017

Help Your Ophthalmologist Help You

Posted in: Latest News, Low Vision Rehabilitation

Please share this article with your ophthalmologist Vision rehabilitation is the standard of care for patients who are losing their vision, and ophthalmologists are key to improving access to care for these patients. Recognizing this, Lighthouse Guild is offering ophthalmologists free access to an eLearning program titled, “Introduction to Vision Rehabilitation.” Dr. Alan R. Morse,
read more »

December 6, 2017

Iluvian Continues to Show Good Results in DME Trials

Posted in: Latest News, Research and Developments

We reported here in 2015 that Iluvian, a unique drug implant devised by Alimera Sciences, had entered trials for treatment of diabetic macular edema (DME). The drug is a corticosteroid that has demonstrated effectiveness in the treatment of DME without the need for monthly injections. Jay Prensky, MD (investigator for Alimera Sciences) reported to the
read more »

December 5, 2017

Invitation to be a Hadley Advisor

Posted in: Latest News

An invitation from Julie Tye at the Hadley Institute for the Blind and Visually Impaired Having just celebrated my first anniversary as president of Hadley, I want to take this opportunity to share my enthusiasm for our future together and to ask for your help. Over the course of the past year, I have grown
read more »

December 5, 2017

Headworn Video Devices Are Helping The Visually Impaired To See Better

Posted in: Daily Living, Latest News

by Dan Roberts (Updated 12/4/2017) Portable electronic magnifiers have come a long way in the past decade, improving clarity of vision for thousands. A natural development for those who prefer to have their hands free has been the creation of several types of headworn video devices, the leaders in the field being eSight, NuEyes, and
read more »

November 27, 2017

LowViz Guide Builds Mental Mapping Skills

Posted in: Latest News, Low Vision Rehabilitation

by Dan Roberts Independently navigating the environment, both indoors and out, is now possible for blind and visually impaired individuals. Making that a reality are audible portable global positioning systems (GPS) and radio signaling beacons paired with smart phones. And just as exciting, this new miracle of accessibility has stirred renewed interest in something equally
read more »

November 27, 2017

Regeneron Study of Nesvacumab Discontinued

Posted in: Latest News, Research and Developments

It was recently reported here that nesvacumab (REGN910) was being tested in combination with Eylea (Regeneron) as a potential treatment for wet AMD. Regeneron, however, reported on November 27 that the results “did not provide sufficient differentiation to warrant Phase 3 development.” The Phase 2 trials have, therefore, been discontinued, and research data will be
read more »

November 20, 2017

Two New Antiangiogenic Drugs Under Study for Wet AMD and DME

Posted in: Latest News, Research and Developments

Since 2005, anti-VEGF drug injections have proved effective for treatment of neovascularization* secondary to age-related macular degeneration (AMD) and diabetic macular edema (DME). Several newer anti-VEGF therapies are also under study, including PAN-90806, OPT-302, ICON-1, RGX-314, and RTH258. All of these are described and sourced on this site. Recently, scientists have researched a possible counterpart
read more »

November 18, 2017

Incidence of AMD Dramatically Declining

Posted in: Latest News, Research and Developments

A recent observational study at the University of Wisconsin-Madison has found that the risk of developing age-related macular degeneration (AMD) has been dramatically lessening over three generations. After looking at follow-up data on 4,819 participants and their offspring in the Beaver Dam studies (1987-2013), Karen J. Cruickshanks, Ph.D. et al found that the incidence of
read more »

November 16, 2017

Two Trials Take First Step Toward Stem Cell Treatment for AMD

Posted in: Latest News, Research and Developments

Results from two new clinical trials have added support for the use of human embryonic stem cells as treatment for the dry form of macular degeneration. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients’
read more »

November 16, 2017

Seeing AI Now Available Outside of U.S.

Posted in: Latest News

We announced here in July that Microsoft had released Seeing AI,  a free app that harnesses the power of Artificial Intelligence (AI) to audibly read text, identify objects, and describe people. The app was originally available only in the United States, but it is now also in the British, Irish and Australian App stores. It is still available only for iOS devices
read more »

November 11, 2017

Brolucizimab May Be the Next Treatment Option for Wet AMD

Posted in: Latest News, Research and Developments

Swiss drugmaker Novartis has announced that their new anti-VEGF drug, brolucizumab (RTH258), is meeting expectations as a potentially more effective and longer lasting treatment for wet macular degeneration than at least one of the current options. Positive results from two Phase III studies of brolucizumab versus aflibercept (Eylea) were presented at the American Academy of
read more »

Page 1 of 3012345...102030...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann